BrightGene Bio-Medical Technology Co., Ltd.
Research BrightGene Bio-Medical Technology Co., Ltd. (688166.SS) on Bullrun: market cap CNY 13.18B, P/E 126.0, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688166.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 13.18B
- P/E126.0
- Dividend yield0.1%
- Financial periodQ2 2026
- RevenueCNY 353.16M
- Net incomeCNY 49.64M
- Free cash flowCNY 57.97M
- Gross margin53.9%
Valuation Snapshot
latest market cap is CNY 13.18B; P/E is 126.0; dividend yield is 0.1%.
Peer valuation comparison
Latest P/E is 126x versus a Healthcare sector median of 21.8x (478.1% above).
Latest dividend yield is 0.05% versus a Healthcare sector median of 2.4% (97.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 13.18B | 126.0 | 0.1% | 0.02 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.02 CNY, yield 0.1%.
About BrightGene Bio-Medical Technology Co., Ltd.
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates;
ETFs that hold BrightGene Bio-Medical Technology Co., Ltd.
US-listed ETFs
BrightGene Bio-Medical Technology Co., Ltd. is held by 10 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BrightGene Bio-Medical Technology Co., Ltd.'s market cap?
BrightGene Bio-Medical Technology Co., Ltd.'s market capitalization is CNY 13.18B.
What is BrightGene Bio-Medical Technology Co., Ltd.'s P/E ratio?
BrightGene Bio-Medical Technology Co., Ltd.'s price-to-earnings (P/E) ratio is 126.0.
Does BrightGene Bio-Medical Technology Co., Ltd. pay a dividend?
BrightGene Bio-Medical Technology Co., Ltd. has a dividend yield of 0.1%.
What does BrightGene Bio-Medical Technology Co., Ltd. do?
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development.